Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012
Tue, October 23, 2012
Mon, October 22, 2012
Sun, October 21, 2012
Sat, October 20, 2012
Fri, October 19, 2012

Bernstein Liebhard LLP Announces Investigation Into Abiomed, Inc.


//health-fitness.news-articles.net/content/2012/ .. lp-announces-investigation-into-abiomed-inc.html
Published in Health and Fitness on Friday, November 2nd 2012 at 14:32 GMT by Market Wire   Print publication without navigation


Bernstein Liebhard LLP Announces Investigation Into Abiomed, Inc.

NEW YORK, Nov. 2, 2012[ Bernstein Liebhard LLP ] today announced an investigation into Abiomed, Inc. (NASDAQ: [ ABMD ]) ("Abiomed" or the "Company") relating to the Company's marketing and labeling of its Impella 2.5 heart pump.  Abiomed is a purported pioneer in healthcare technology and innovation and is famous for the world's first total replacement heart and the world's smallest heart pump. The Impella 2.5 pump is designed to provide short-term circulatory support for heart patients.

(Logo: [ http://photos.prnewswire.com/prnh/20120202/MM47134LOGO ] )

On November 1, 2012, Abiomed issued a press release stating that the United States Attorney's Office for the District of Columbia had notified the Company on October 26, 2012 that it was conducting an investigation focusing on the marketing and labeling of the Impella 2.5.  On October 31, 2012, Abiomed accepted service of a Health Insurance Portability and Accountability Act administrative subpoena related to this investigation. The subpoena seeks documents related to the Impella 2.5 and focuses primarily on marketing and labeling issues. 

Abiomed's announcement follows a June 2011 warning letter from the United States Food and Drug Administration accusing the Company of making unsubstantiated and unauthorized efficacy claims about the Impella 2.5 system in its marketing materials. 

After the Company's adverse announcement on November 1, 2012, Abiomed stock plunged from a $19.82 closing price on October 31, 2012 to close at $13.61 on November 1, 2012 -- losing almost a third of its value.

If you are interested in discussing your rights as an Abiomed shareholder and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or [ seidman@bernlieb.com ].

[ Bernstein Liebhard LLP ] has pursued hundreds of securities, [ consumer ] and shareholder rights cases and recovered over $3 billion for its clients.  It has been named to The National Law Journal's "Plaintiffs' Hot List" in each of the last ten years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
[ www.bernlieb.com ]

SOURCE Bernstein Liebhard LLP



RELATED LINKS
[ http://www.bernlieb.com/ ]

Publication Contributing Sources